Thursday, 15 October 2026European Markets

AUGROS COSMETICS Stock Impressive Rise 15% So Far On Monday, Outperforms Market

Loading stream...

(vianews) - shares of augros cosmetics (cac 40: augr.pa) rose by a staggering 15.94% to €8.00 at 14:37 est on monday, after two sequential sessions in a row of gains. cac 40 is sliding 0.12% to €7,262.01, after two successive sessions in a row of gains. this seems, at the moment, a somewhat bearish trend exchanging session today.

about augros cosmetics

augros cosmetic packaging sa provides customized packaging solutions in france. the company offers decoration solutions for glass, plastic, and aluminum packaging materials. it serves the perfume, cosmetic, and spirit industries. the company is based in alencon, france. augros cosmetic packaging sa operates as a subsidiary of famille bourgine.

earnings per share

as for profitability, augros cosmetics has a trailing twelve months eps of €0.45.

pe ratio

augros cosmetics has a trailing twelve months price to earnings ratio of 17.78. meaning, the purchaser of the share is investing €17.78 for every euro of annual earnings.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com